Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00321009 · ClinicalTrials.gov registry record · NA
LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin
A NA study, sponsored by Corewell Health East.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT00321009 is a NA study that has completed, run by Corewell Health East. The registered enrollment target is 60 participants.
The verdict
NCT00321009, a NA study, has completed, sponsored by Corewell Health East.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
To prospectively evaluate the utility of enoxaparin vs. oral warfarin in reduction of echocardiographic indices of LV mural thrombus. The primary outcome is the presence of LV mural thrombus at 3.5 months. The secondary outcome is cost analysis comparing the two arms.
Interventions
- DRUG Enoxaparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2000-03 |
| Est. Completion | 2004-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00321009
The ClinicalTrials.gov registry entry for NCT00321009 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health East, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enoxaparin is the first listed.
NCT00321009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00321009 about?
NCT00321009 is a clinical study titled "LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin". To prospectively evaluate the utility of enoxaparin vs. oral warfarin in reduction of echocardiographic indices of LV mural thrombus. The primary outcome is the presence of LV mural thrombus at 3.5 months. The secondary outcome is cost analysis comparing the two arms.
What is the current status of trial NCT00321009?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2000-03. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00321009?
The interventions under investigation include: Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT00321009?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.